La Innovative Medicine Initiative ha lanciato la IMI2 Call 13.
I topic sono i seguenti:
- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Pilot programme on a clinical compound bank for repurposing (This programme includes the following topics: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; rare/orphan diseases)
A seguito di una discussione in proposito tra IMI Office, EFPIA e EC, il topic “Development of a Platform for Federated and Privacy-Preserving Machine Learning in Support of Drug Discovery” è stato ritirato dalla Call 13. Tuttavia, esso sarà preso in considerazione per future call.
La deadline per inviare le proposte è il 28 Febbraio 2018.
Clicca qui per il testo orginale.
Inoltre, dallo scorso lunedì 27 novembre, è iniziata la serie di Webinar specifici sui vari Topic della Call 13. E’ ancora possibile registrarsi alla maggior parte di essi visitando la pagina ufficiale.
La registrazione è gratuita ma obbligatoria.
